KPC 在铜绿假单胞菌中的存在对碳青霉烯类治疗的体内疗效影响极小。
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
机构信息
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
出版信息
Antimicrob Agents Chemother. 2013 Feb;57(2):1086-8. doi: 10.1128/AAC.01748-12. Epub 2012 Dec 17.
Abstract
While reports of Klebsiella pneumoniae carbapenemase (KPC) production among Pseudomonas aeruginosa strains have emerged from a number of countries worldwide, outcome data are lacking. This is the first report evaluating how KPC production in P. aeruginosa impacts the efficacy of carbapenems by using the murine thigh infection model. Our findings suggest that the impact of KPC-2 in vivo is less pronounced than would be anticipated based on the in vitro potency.
摘要
虽然世界各地有许多国家报告了铜绿假单胞菌中产碳青霉烯酶（KPC）的情况，但缺乏相关结果数据。这是首次使用小鼠大腿感染模型评估铜绿假单胞菌中产 KPC 对碳青霉烯类药物疗效的影响的报告。我们的研究结果表明，KPC-2 体内的影响比体外效力所预期的要小。
相似文献
1
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Antimicrob Agents Chemother. 2013 Feb;57(2):1086-8. doi: 10.1128/AAC.01748-12. Epub 2012 Dec 17.
2
Characterization of acquired β-lactamases in and quantification of their contributions to resistance.
Microbiol Spectr. 2024 Oct 3;12(10):e0069424. doi: 10.1128/spectrum.00694-24. Epub 2024 Sep 9.
3
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Int J Antimicrob Agents. 2012 Jan;39(1):11-5. doi: 10.1016/j.ijantimicag.2011.08.018. Epub 2011 Nov 1.
4
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Antimicrob Agents Chemother. 2014;58(3):1678-83. doi: 10.1128/AAC.01947-13. Epub 2013 Dec 30.
5
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Antimicrob Agents Chemother. 2013 Aug;57(8):3936-40. doi: 10.1128/AAC.00708-13. Epub 2013 Jun 3.
6
Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Antimicrob Agents Chemother. 2011 Dec;55(12):5597-601. doi: 10.1128/AAC.00742-11. Epub 2011 Oct 3.
7
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Antimicrob Agents Chemother. 2010 Jul;54(7):3076; author reply 3076-7. doi: 10.1128/AAC.00472-10.
8
Emergence of KPC-2-producing Pseudomonas aeruginosa sequence type 463 isolates in Hangzhou, China.
Antimicrob Agents Chemother. 2015 May;59(5):2914-7. doi: 10.1128/AAC.04903-14. Epub 2015 Feb 17.
9
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
J Antimicrob Chemother. 2013 Jul;68(7):1616-8. doi: 10.1093/jac/dkt056. Epub 2013 Mar 8.
10
Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa.
Crit Rev Microbiol. 2010 Aug;36(3):245-58. doi: 10.3109/1040841X.2010.481763.
引用本文的文献
1
Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Türkiye.
Eur J Clin Microbiol Infect Dis. 2025 Jan;44(1):159-165. doi: 10.1007/s10096-024-04990-w. Epub 2024 Nov 15.
2
In vivo studies on antibiotic combination for the treatment of carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis protocol.
BMJ Open Sci. 2020 Jul 21;4(1):e100055. doi: 10.1136/bmjos-2019-100055. eCollection 2020.
3
Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.
Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1211-1220. doi: 10.1007/s10096-018-3244-4. Epub 2018 Apr 11.
本文引用的文献
1
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. doi: 10.1128/AAC.01420-10. Epub 2011 Mar 21.
2
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Antimicrob Agents Chemother. 2010 Mar;54(3):1354-7. doi: 10.1128/AAC.00899-09. Epub 2009 Dec 28.
4
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Oct;53(10):4352-6. doi: 10.1128/AAC.00282-09.
5
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
Antimicrob Agents Chemother. 2009 Apr;53(4):1660-4. doi: 10.1128/AAC.01172-08. Epub 2009 Feb 2.
6
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Antimicrob Agents Chemother. 2008 Jul;52(7):2497-502. doi: 10.1128/AAC.01252-07. Epub 2008 May 5.
7
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.
Clin Infect Dis. 2008 Jun 1;46(11):e127-30. doi: 10.1086/588048.
8
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.
J Clin Microbiol. 2007 Aug;45(8):2723-5. doi: 10.1128/JCM.00015-07. Epub 2007 Jun 20.
9
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
Antimicrob Agents Chemother. 2007 Apr;51(4):1481-6. doi: 10.1128/AAC.00752-06. Epub 2007 Feb 5.
10
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
Antimicrob Agents Chemother. 2007 Apr;51(4):1553-5. doi: 10.1128/AAC.01405-06. Epub 2007 Jan 29.
Zotero 插件